Drug Trial Radar · NCT06300723
Clinical Study of BRL-101 in Severe SCD
Last checked: Nov 19, 2026Latest source record: Jul 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
3
Planned (sponsor's estimate)
Start
Jul 29, 2024
Primary completion
Mar 20, 2026
Study completion Jun 15, 2026
Sponsor
- Lead sponsor
- Bioray LaboratoriesIndustry
- Sponsor type
- Industry
- Collaborators
- First Affiliated Hospital of Guangxi Medical University
- First posted
- Mar 8, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single center, non-randomized, open label, single-dose study in subjects with Sickle Cell Disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (BRL-101).
Conditions
- Sickle Cell Disease
Interventions
BRL-101Drug
CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of stem cell engrafted subjectsTime frame: Within 42 Days After BRL-101 Infusion
- Time to neutrophil engraftmentTime frame: Within 42 Days After BRL-101 Infusion
- Frequency, severity, and relationship to BRL-101 of adverse events over 12 months following BRL-101 infusionTime frame: Up to 12 Months After BRL-101 Infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.